Skip to main content

Table 3 Meta-analyses on cancer risks associated with the use of biologics to treat IMIDs

From: Cancer risk in immune-mediated inflammatory diseases (IMID)

Study Disease Study types included Medication Findings
Bongartz et al. 2006 [119] RA Prosp Obs Infliximab Adalimumab Increased risk of malignancies
Peyrin-Biroulet et al. 2008 [120] Crohn’s disease RCTs Infliximab, adalimumab, certolizumab, CDP571 No increase in malignancy
Leombruno et al. 2009 [121] RA RCTs Etanercept, infliximab, adalimumab No increased risk of melanoma, lymphoma, non-lymphoma skin cancer, or cutaneous cancer + melanoma
Bongartz et al. 2009 [122] RA RCTs Etanercept for ≥ 12 weeks Non-significant increase in cancer
Siegel et al. 2009 [123] Adult Crohn’s disease RCTs Infliximab, adalimumab, certolizumab Increase risk of non-Hodgkin’s lymphoma
Mariette et al. 2011 [124] RA Prosp Obs Anti-TNF No increase in malignancy (including lymphoma). Increase in skin cancer (including melanoma)
Dommasch et al. 2011 [125] Plaque psoriasis, psoriatic arthritis RCTs Etanercept, Infliximab, adalimumab, certolizumab, golimumab No increase in cancers for short-term use
Askling et al. 2011 [126] Any RCTs etanercept, infliximab, adalimumab No increase in cancer with short-term use
Campbell et al. [127] RA RCTs Tocilizumab No increase in risk of malignancy
Lopez-Olivo et al. [128] RA RCTs Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Abatacept, Anakinra, Rituximab, Tocilizumab No increased risk of malignancy in comparison with DMARDs or placebo
Moulis et al. 2012 [129] RA RCTs Anti-TNF No excess cancer risk in either per protocol or intention to treat analysis, non-significant trend for increased non-melanoma skin cancer
  1. Abbreviations: DMARDs Disease-modifying anti-rheumatic drugs, IMID immune-mediated inflammatory disease, RCT randomized clinical trial, Prosp Obs prospective observational trial.